Abstract

Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to the X-ray diffraction crystallography expanded for the position delta 9-12.5 (2 theta), to a patient suffering from said disorder. There is also disclosed a method for preparing a composition according to the invention, where the alprazolam is solved in a pharmaceutical acceptable solvent and a binder, preferably polyvinylpyrrolidone, is incorporated to the solution. A pre-made mixture of part of the cross-linked carboxymethyl-cellulose and the rest of the ingredients of the composition is impregnated with the solution and is dried and grinded, and is added to the rest of the cross-linked carboxymethyl-cellulose and the flavoring additives, being then mixed and compressed.


Claims
Download PDF
Document Preview
Document History
  • Publication: Apr 17, 2014
  • Application: Dec 11, 2013
    US US 201314102934 A
  • Priority: Dec 11, 2013
    US US 201314102934 A
  • Priority: Feb 2, 2009
    US US 36380209 A
  • Priority: Feb 5, 2008
    EP EP 08002077 A

Sign in to the Lens